TG Therapeutics

Pricing Pressures And Competitive Risks Will Impair Market Strength

AnalystLowTarget

Not Invested

Community Contributor

Published

04 May 25

Updated

08 May 25

AnalystLowTarget's Fair Value

US$12.34

197.1% overvalued

10 Sep

US$36.66

65.2%

5.8%

65.2%

5.8%

You can edit this narrative until May 12 6:00 AM. Then, changes will post as Updates.

Author's Valuation

US$12.34197.1% overvalued

AnalystLowTarget Fair Value

Narrative

Updates1

Shared on08 May 25

AnalystLowTarget Fair Value

US$12.34

197.1% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

26.32%

Biotech revenue growth rate

8.32%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.83%

Calculation

US$344.67m

Earnings '28

6.67x

PE Ratio '28

US$2.30b

Market Cap '28

US$2.30b

Market Cap '28

153.26m

No. shares '28

US$15.00

Share Price '28

US$15.00 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$12.32

Fair Value '25